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ART adherence and viral suppression are high among most
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infection: an observational study from Uganda and South Africa
Jessica E Haberer1,2§ , Bosco M Bwana3,4, Catherine Orrell5,6, Stephen Asiimwe4,7, Gideon Amanyire4,8,9,
Nicholas Musinguzi4, Mark J Siedner1,2,9, Lynn T Matthews1,2, Alexander C Tsai1,2, Ingrid T Katz2,10, Kathleen Bell1,
Annet Kembabazi4, Stephen Mugisha4, Victoria Kibirige4, Anna Cross5, Nicola Kelly5, Bethany Hedt-Gauthier1,2 and
David R Bangsberg11
§Corresponding author: Jessica E Haberer, MGH Center for Global Health, 125 Nashua Street, Suite 722, Boston, Massachusetts 02114, USA. Tel:
+1 617 724 0351 (jhaberer@mgh.harvard.edu)
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Abstract
Introduction: The success of universal antiretroviral therapy (ART) access and aspirations for an AIDS-free generation depend
on high adherence in individuals initiating ART during early-stage HIV infection; however, adherence may be difficult in the
absence of illness and associated support.
Methods: From March 2015 to October 2017, we prospectively observed three groups initiating ART in routine care in
Uganda and South Africa: men and non-pregnant women with early-stage HIV infection (CD4 > 350 cells/lL), pregnant
women with early-stage HIV infection and men and non-pregnant women with late-stage HIV infection (CD4 < 200 cells/lL).
Socio-behavioural questionnaires were administered and viral loads were performed at 0, 6 and 12 months. Adherence was
monitored electronically.
Results: Adherence data were available for 869 participants: 322 (37%) early/non-pregnant, 199 (23%) early/pregnant and
348 (40%) late/non-pregnant participants. In Uganda, median adherence was 89% (interquartile range 74 to 96) and viral sup-
pression was 90% at 12 months; neither differed among groups (p > 0.72). In South Africa, median adherence was higher in
early/non-pregnant versus early/pregnant or late/non-pregnant participants (76%, 37%, 52%; p < 0.001), with similar trends in
viral suppression (86%, 51%, 79%; p < 0.001). Among early/non-pregnant individuals in Uganda, adherence was higher with
increasing age and lower with structural barriers; whereas in South Africa, adherence was higher with regular income, higher
perceived stigma and use of other medications, but lower with maladaptive coping and cigarette smoking.
Discussion: ART adherence among non-pregnant individuals with early-stage infection is as high or higher than with late-stage
initiation, supporting universal access to ART. Challenges remain for some pregnant women and individuals with late-stage
infection in South Africa and highlight the need for differentiated care delivery.
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1 | INTRODUCTION
Global aspirations for an AIDS-free generation are inspired by
data showing that antiretroviral therapy (ART)-mediated HIV
viral suppression reduces HIV transmission risk by 96% [1,2],
and recent studies provide strong evidence that unde-
tectable = untransmissible (U = U) [3,4]. Moreover, two ran-
domized controlled trials demonstrated wide-ranging health
benefits of immediate versus delayed ART, even at relatively
high CD4 counts [5,6]. These findings have led to World
Health Organization (WHO) treatment guidelines to initiate
ART for all people living with HIV (PLWH) regardless of CD4
count [7]. Notably, these guidelines assume that adherence
does not vary by HIV disease stage at ART initiation. If
patients with early-stage disease have low adherence, ART
expansion could be accompanied by high levels of viraemia,
poor health, drug resistance, and/or increased secondary HIV
transmission [8] - all of which would mitigate the clinical and
preventive benefits of early ART.
ART adherence during late-stage HIV disease has typically
been high in sub-Saharan Africa among those engaged in care
and has been thought to be driven largely by social network
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activation to overcome adherence barriers [9]. Social support
helps PLWH overcome structural and economic barriers to
adherence (e.g. living in geographically remote areas and need-
ing to pay high transportation costs to pick up ART) [10,11].
Access to social support, however, requires HIV status disclo-
sure, which may be less common in early-stage disease due to
HIV stigma [12–15]. These issues may be particularly relevant
during pregnancy and post-partum when numerous social and
biological stressors may converge [16]. Moreover, illness is
often a strong catalyst for encouraging HIV disclosure, which
enables PLWH to access the support needed to achieve high
ART adherence. Yet, symptomatic illness is less prominent for
individuals with early-stage HIV infection [16,17].
Data are sparse on adherence and treatment outcomes
among people presenting early to care in programmatic set-
tings, partially because of the persistence of late presentation
to care and treatment initiation and particularly in sub-
Saharan Africa [18–20]. A recently published systematic
review and meta-analysis found that patients with higher
(vs. lower) CD4 counts were less likely to achieve excellent
adherence, although many studies found no difference
between these groups [21]. Importantly, adherence monitoring
was limited to self-report and/or pharmacy data in all studies
and none of the six prospective studies involved patient follow
up after 2010, when the recommended CD4 count threshold
for initiating treatment increased to 350 cells/lL. The meta-
analysis authors therefore called for additional high-quality
studies, particularly among adults initiating ART at higher
CD4 cell counts.
In this study, we prospectively observed three groups of
individuals initiating ART in routine care in southwestern
Uganda and Cape Town, South Africa over 12 months, using
electronic adherence monitors to provide a detailed, objective
assessment of adherence behaviour. The groups included men
and non-pregnant women with early-stage HIV infection
(CD4 > 350 cells/lL); pregnant women with early-stage HIV
infection; and men and non-pregnant women with late-stage
HIV infection (CD4 < 200 cells/lL). Here, we present the
levels of adherence and viral suppression among these groups
with a goal of testing our hypothesis that ART adherence may
be lower in individuals with early-stage HIV infection at ART
initiation (with and without pregnancy) compared to those
with late-stage infection. Among those with early-stage HIV
infection, we also explore which socio-behavioural factors may
influence their adherence.
2 | METHODS
2.1 | Study settings
In Uganda, participants were recruited from the Mbarara
Regional Referral Hospital, Mbarara Municipal Council Health
Centre IV, Kabwohe Clinical Research Centre, Kabwohe
Health Centre IV and Health Center III facilities in Mushanga,
Kakoba and Nyamitanga. All are located approximately
275 km from Kampala in a largely rural area, near a peri-
urban centre in Mbarara Town; HIV prevalence is approxi-
mately 8%. In South Africa, participants were recruited from
the Hannan Crusaid Treatment Centre and Vuyani, NY1 and
Nyanga Clinics. All are located in Gugulethu - a township near
Cape Town, South Africa with high levels of poverty; HIV
prevalence is approximately 17%. An estimated 78% of all
individuals in care in both Uganda and South Africa are virally
suppressed [22].
2.2 | Participants
Individuals were recruited between March 2015 and Septem-
ber 2016 into one the following three groups using conve-
nience sampling as they presented for HIV care:
1 “Early/non-pregnant”: men and non-pregnant women living
with HIV and initiating ART with asymptomatic early-stage
HIV infection (CD4 > 350 cells/lL; WHO stage I)
2 “Early/pregnant”: pregnant women living with HIV and initi-
ating ART with asymptomatic early-stage HIV infection
(CD4 > 350 cell/lL; WHO stage I)
3 “Late/non-pregnant”: men and non-pregnant women living
with HIV and initiating ART with late-stage HIV infection
(CD4 < 200 cells/lL).
Inclusion criteria were being ART-na€ıve and initiating ART
within 28 days of enrolment, >18 years old, living within
60 km of the clinic, and intending to stay in the area for one
year. We did not enrol individuals with CD4 counts between
200 and 350 cells/lL because immunological status in this
range has less clear associations with health compared to
lower and higher CD4 counts. A “late/pregnant” group was
not enrolled due to limited resources. Pregnant participants
had to be <34 weeks in pregnancy per best available esti-
mates at enrolment. The only exclusion criteria were cognitive
impairment (e.g. intoxication or psychosis) such that informed
consent could not be obtained or the inability to communicate
in English or the primary local languages (i.e. Runyankole in
Uganda and Xhosa in South Africa).
2.3 | Study procedures
Participants received routine care at their local clinics. Stan-
dard first-line ART (once daily tenofovir/emtricitabine/efavir-
enz in a single pill) was provided by the study to avoid
variations in adherence due to regimen stock outs; changes in
ART were made per routine clinical guidance. Participants
were seen for study visits at baseline, 6 and 12 months. Con-
tact between study staff and participants in between visits
was infrequent, by design, to minimize influence of the study
on participant behaviour and only occurred to troubleshoot
technical problems with the adherence monitors. At study vis-
its, participants provided blood for viral load (determined by
Cobas Taqman Test in Uganda and Roche CAP/CTM HIV-1
v2 assay in South Africa) and research assistants administered
surveys on handheld tablets. All materials were presented in
the participant’s preferred language (i.e. English, Runyankole,
or Xhosa), and accuracy of translations were confirmed with
back translations. Socio-behavioural factors potentially rele-
vant for adherence were chosen based on the Behavioral
Model for Vulnerable Populations [23] and included socio-
demographics, structural barriers to care (scale of 0 to 52,
higher score indicating more barriers [24]), severe food inse-
curity (Household Food Insecurity Access Scale [25]), HIV
stigma (scale 1 to 4, higher score indicating more stigma,
adapted Berger HIV Stigma Scale [26]), HIV disclosure, coping
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(scale of 1 to 4, higher score indicating maladaptive coping
[27]), medical mistrust/conspiracy (scale 1 to 4, higher score
indicating more mistrust/conspiracy [28]), necessity and con-
cerns about taking ART [29], clinic satisfaction (scale 1 to 4,
higher score indicating more satisfaction; adapted from [30]),
mental and physical health (Medical Outcomes Study-HIV,
normalized with 50 indicating average health in a U.S. popula-
tion [31]), depression symptom severity (Hopkins Symptom
Checklist, probable depression indicated by an average score
of >1.75 [32]) and alcohol use (AUDIT-C [33]). The degree of
emotional or instrumental support received from social net-
work ties was assessed by using name generator question-
naires to elicit up to 20 ties, each of whom were rated for the
degree of support provided to the participant [34]. The social
support score reflects the proportion of each participant’s
supporters at each study visit who were categorized as com-
pletely supportive. Adherence was monitored with a real-time
electronic adherence pill container. Each time the monitor was
opened for presumed medication ingestion, a date-and-time
stamp was recorded and transmitted over the cellular net-
work; the monitor additionally sent a daily “heartbeat” to indi-
cate device functionality (Wisepill Technologies, South Africa).
Research assistants explained the purpose and function of the
device to participants at enrolment, asking them to store only
their ART in the device and remove one dose at a time. If par-
ticipants were hesitant to use the monitor (e.g. due to travel),
they were advised to use an alternate pill container during
those periods.
2.4 | Statistical analysis
Participant characteristics were summarized descriptively.
Comparisons between sites were made with Wilcoxson rank
sum and Pearson’s chi-square tests for continuous and cate-
gorical variables respectively. Adherence was calculated as the
number of adherence monitor opening events received divided
by the number of monitor opening events expected during fol-
low up. Adherence was capped at 100% per day and censored
at death. Adherence for participants lost to follow up (defined
as no contact despite multiple attempts through 13 months
after enrolment) was calculated until the device stopped trans-
mitting data or until the last scheduled study visit - whichever
came first. Monitor opening events were removed from the
data set for staff openings and during periods of known device
malfunction. A secondary data set was created in which device
non-use as reported by participants was also removed. Adher-
ence interruptions of 7+ days were assessed, as this duration
of non-adherence has been associated with >5% risk for virae-
mia [35]. Participants were considered viraemic if they died or
were lost to follow up, or missed visits and had <80% adher-
ence in the month before the visit. If a visit was missed in
South Africa, available viral load data within one month of the
visit were obtained through the National Health Laboratory
Service, a previously validated approach [36].
Adherence distributions between groups were compared
with the Kruskal Wallis test. Viral suppression was defined as
<400 copies/mL and compared among groups by Pearson’s
chi-square test. Changes over time were assessed by condi-
tional linear regression. A pre-planned interim analysis was
conducted once half of participants reached the 6-month time
point to determine the need for early termination of the
study; no comparisons met the pre-specified criteria. To test
our hypothesis that adherence may differ by HIV stage at
ART initiation, we ran linear generalized estimating equa-
tion (GEE) regression models; cluster-correlated robust esti-
mates of variance were used to account for within-participant
dependence of observations. Confounders were identified by
a significance level of p < 0.10 in univariable models and
retained in multivariable models. Uganda and South Africa
sites were analysed separately because of numerous demo-
graphic and socio-economic differences between them.
Because of collinearity, emotional social support was removed
and instrumental social support was retained. We ran similar
linear GEE models to assess for adherence predictors among
non-pregnant individuals with early-stage HIV infection. All
analyses were conducted in Stata 13 (StataCorp., College Station,
TX, USA).
2.5 | Ethics
This study was approved by all relevant institutional review
boards: Partners Healthcare/Massachusetts General Hospital,
Mbarara University of Science and Technology, Uganda
National Council for Science and Technology, University of
Cape Town and Western Cape province in South Africa. All
participants provided written informed consent.
3 | RESULTS
3.1 | Participant characteristics
We screened 2258 participants and enrolled 904 between
March 2015 and September 2016, including 483 in Uganda
and 421 in South Africa (Figure 1). The most common reason
for exclusion was a CD4 count between 200 and 350 cells/
lL (n = 530, 55%). Seventeen percent of screened partici-
pants (n = 384) were eligible, but did not enrol; no differences
in age, gender or study group were seen in those who did not
versus did enrol in South Africa. However, in Uganda, those
who did not enrol were more likely to be male (42% vs. 31%,
p = 0.002). The distribution across some study groups also dif-
fered, comparing those who did not versus did enrol: early/
non-pregnant group (39% vs. 37%; p = 0.62), early/pregnant
group (16% vs. 26%; p = 0.002) and late/non-pregnant (45%
vs. 37%; p = 0.05). Identifying eligible pregnant women was
challenging due to restrictive enrolment criteria and compet-
ing studies, resulting in lower numbers in this group compared
to the other groups. Contact with participants in between
study visits for technical challenges with the adherence moni-
tors occurred at least once in 89 (10%) participants, with a
mean number of challenges of 2 (standard deviation 1.3)
among those with any challenges.
Numerous demographic and socio-behavioural differences
were seen between the two settings (Table 1). The most nota-
ble differences included younger age, higher proportion of
marriage, lower education, higher employment, higher per-
ceived need for ART and more use of medications other than
ART in Uganda. Additionally, structural barriers and food inse-
curity were higher in South Africa, as were probable depres-
sion, heavy alcohol use and cigarette use. Participant
characteristics by group are shown in the Appendix
(Table A1).
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In Uganda, we found the following factors to be significantly
associated with ART adherence: [positively] increasing age
(p = 0.002), employment (p = 0.02), instrumental support
(p < 0.001) and use of medications other than ART (p = 0.02);
[negatively] sex work (p = 0.003), structural barriers (p =
0.006) and severe food insecurity (p = 0.03). In South Africa,
we found the following factors to be significantly associated
with ART adherence: [positively] increasing age (p = 0.04)
and employment (p = 0.04); [negatively] instrumental support
(p = 0.004), maladaptive coping (p = 0.03) and cigarette
Parcipants screened (n = 2258)
Ineligible (n = 970*)
• CD4 200-350 cells/µl (n = 530)
• CD4 >350 cells/µl with WHO stage >1 (n = 122)
• ART experienced (n = 98)
• Lived outside catchment area (n = 95)
• Not intending to live in area 1+ years (n = 47)
• Pregnant with a CD4 <350 cells/µl (n = 24)
• Age <18 years (n = 22)
• Not iniang ART in next 28 days (n = 15)
• Pregnant >34 weeks (n = 13)
• Mentally unstable (n = 6)
• Language barrier (n = 3)
Adherence assessed (n = 869)
• Graduated (n = 803)
• Died (n = 31)
• Lost to follow-up (n = 29)
• Withdrew due to preference or moving 
out of catchment (n = 6)
Eligible (n = 1288)
*Five parcipants met mulple exclusion criteria
Not enrolled (n = 384)
• Not interested/me barred/unknown (n = 311)
• Too weak to parcipate (n = 31)
• Family/other person’s influence (n = 23)
• Sgma (n = 15)
• Declined blood draws (n = 4)
Enrolled (n = 904)
Not issued an electronic adherence monitor (n = 35)
• Graduated (n = 2)
• Died (n = 5)
• Disenrolled 
o Ineligible aer consent (n = 18)
o Sgma (n = 2)
o No longer interested in study (n = 6)
o Unknown/other (n = 2)
Figure 1. Flow diagram of participant screening, enrolment and follow-up.
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Table 1. Baseline participant characteristics (N = number; SD = standard deviation)
Characteristic Uganda South Africa p-Value
Enrollment (N) 483 421 –
Group (N, %) 0.004
Early/non-pregnant 177 (36) 158 (38)
Early/pregnant 129 (27) 76 (18)
Late/non-pregnant 177 (37) 187 (44)
Median CD4 count (cells/lL, IQR)
For participants > 350 469 (411, 593) 435 (387, 485) <0.001
For participants < 200 123 (68, 164) 111 (51, 159) 0.07
Median viral load (log10 copies/mL, IQR) 4.3 (3.1, 4.9) 4.6 (4.0, 5.2) <0.001
Female (N, %) 332 (69) 293 (70) 0.78
Mean age (years, SD) 31 (9) 34 (10) <0.001
Married (N, %) 260 (55) 68 (16) <0.001
Sexually active in the past six months (N, %) 392 (83) 375 (90) 0.005
Highest education (N, %): <0.001
None/primary 188 (40) 56 (13)
Secondary 284 (60) 364 (87)
Literacy (N, %) in the local language (Runyankole or Xhosa) 405 (86) 371 (90) 0.086
Regular income (N, %) 60 (13) 192 (46) <0.001
Employed (N, %) 392 (83) 179 (43) <0.001
Exchange money for sex (N, %) 44 (9) 9 (2) <0.001
Structural barrier score (mean score, SD) 3 (5) 13 (7) <0.001
Instrumental support (mean score, SD) 30 (12) 31 (13) 0.82
Emotional support (mean score, SD) 34 (13) 32 (14) 0.03
Severe food insecurity (N, %) 140 (30) 284 (68) <0.001
Stigma: perceived negative attitudes towards HIV (mean score, SD) 2 (2) 3 (2) <0.001
Stigma: disclosure concerns (mean score, SD) 4 (3) 3 (3) 0.10
Disclosed aside from healthcare provider (N, %) 382 (81) 323 (77) 0.14
Disclosed outside of household (N, %) 254 (54) 147 (35) <0.001
Necessity of ART (N, %) <0.001
High 200 (42) 51 (12)
Moderate 188 (40) 192 (46)
Low 83 (18) 177 (42)
Concern for ART (N, %) <0.001
High 210 (45) 246 (59)
Moderate 174 (37) 154 (37)
Low 87 (18) 20 (5)
Coping score (mean, SD) 2.2 (0.4) 2.4 (0.3) <0.001
Medical mistrust (mean, SD) 1.9 (0.8) 2.1 (0.6) <0.001
Conspiracy (mean, SD) 1.9 (0.7) 2.3 (0.6) <0.001
Clinic satisfaction (mean, SD) 3.5 (0.4) 3.1 (0.4) <0.001
First positive HIV test > 30 days prior to enrolment (N, %) 241 (51) 206 (54) 0.48
Use of medications other than ART (N, %) 386 (82) 85 (20) <0.001
Physical well-being (mean, SD) 39 (5) 42 (8) <0.001
Mental well-being (mean, SD) 46 (12) 38 (9) <0.001
Probable depression (N, %) 114 (24) 207 (49) <0.001
Heavy alcohol use (N, %) 41 (9) 119 (28) <0.001
Cigarette use (N, %) 54 (12) 94 (22) <0.001
ART, antiretroviral therapy; IQR, interquartile range. Data were missing for some characteristics as reflected in the percentage presented. Maxi-
mum missing data was <10%.
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smoking (p = 0.01). We considered these factors as potential
confounders of the relationship between HIV infection stage
and ART adherence in the models testing our main study
hypothesis (below).
Following enrolment, 29 participants were lost to follow up,
6 withdrew (due to participant preference or moving out of
catchment) and 36 participants died (19 in Uganda, 17 in
South Africa; p = 0.94). Most deaths (N = 30; 83%) occurred
in participants initiating ART with late-stage disease and five
occurred before issuing the adherence monitor. Compared to
participants who completed follow up, these participants had
higher viral load. Fewer were married or employed. Structural
barriers were higher and more had severe food insecurity.
More had a recent diagnosis and fewer had used medications
other than ART. They also had fewer disclosure concerns,
lower clinic satisfaction, lower mental well-being and more
cigarette use (Appendix Table A2).
3.2 | Adherence and viral suppression by setting
Technical function of the adherence monitors was documented
for 97% of participant-days of follow up (N = 288,804/
298,398) (Figure 2). Viral suppression data were available for
895 participants (31 of whom did not contribute adherence
data). In Uganda, median ART adherence at 12 months was
89% overall (interquartile range (IQR) 74% to 96%) and the
median number of adherence interruptions of 7+ days was 0
(IQR 0 to 2). Viral suppression was 90% overall; 89%, 91% and
88% for the early/non-pregnant, early pregnant and late/non-
pregnant groups respectively. No differences in overall adher-
ence or viral suppression were seen among the three groups in
this setting (all p > 0.72). However, more 7+ day interruptions
were seen in the early/pregnant group versus early/non-preg-
nant group (p = 0.004), and trended towards a difference with
the late/non-pregnant group (p = 0.06). In South Africa, median
adherence at 12 months was 61% overall (IQR 26 to 86) and
higher in the early/non-pregnant group compared to the early/
pregnant or late/non-pregnant groups (76%, 37% and 52%
respectively; p < 0.001 overall with p < 0.001 for 76% vs. 37%,
p = 0.001 for 76% vs. 52% and p = 0.18 for 37% vs. 52%). Simi-
lar trends were seen in the number of adherence interruptions
of 7+ days (1.4, 2.6 and 2.1 respectively; p = 0.001 overall with
p = 0.001 for 1.4 vs. 2.6, p = 0.002 for 1.4 vs. 2.1 and p = 0.92
for 2.6 vs. 2.1) and viral suppression (86%, 51% and 79%
respectively; p < 0.001 overall with p < 0.001 for 86% vs. 51%,
p = 0.08 for 86% vs. 79% and p < 0.001 for 51% vs. 79%).
Adherence was lower in months 0 to 6 versus months 7 to 12
in both settings with an estimated mean difference of 5.8 per-
centage points (pp) in Uganda (p < 0.001) and 13 pp in South
Africa (p < 0.001). Results from the secondary data set
accounting for device non-use were nearly identical with no sta-
tistically significant differences.
We found similar adherence among the three groups in
Uganda (p = 0.65) when controlling for the above-noted
potential confounders (Table 2). In South Africa, however,
adherence was significantly higher among non-pregnant indi-
viduals with early-stage HIV infection compared to pregnant
women with early-stage infection and men and non-pregnant
women with late-stage infection (19.2 and 12.1 pp respec-
tively; p < 0.001).
3.3 | Predictors of adherence among non-pregnant
individuals starting ART with early-stage HIV
infection
In Uganda, adherence was significantly higher among non-
pregnant individuals starting ART with early-stage HIV infec-
tion with increasing age (0.5 pp; p < 0.001) and lower with
increasing structural barriers (2.0 pp; p = 0.005) (Tables 3
and 4). In South Africa, adherence in this population was sig-
nificantly higher with a regular income (6.7 pp; p = 0.04),
higher perceived stigma (negative attitudes towards HIV;
1.9 pp; p = 0.04) and use of medications other than ART (9.8 pp,
p = 0.005), but lower with maladaptive coping (14.4 pp;
p = 0.002) and cigarette smoking (12.0 pp; p = 0.007).
4 | DISCUSSION
In this large, observational cohort study of individuals enrolled
in routine HIV care in Uganda and South Africa, we found that
electronically monitored adherence and viral suppression
among individuals initiating ART with early-stage HIV infection
were as high or higher than those initiating ART with late-
stage HIV infection. In Uganda, adherence was generally high
and did not differ by stage of ART initiation or pregnancy,
although adherence interruptions of 7+ days were higher in
pregnant women; viral suppression achieved the UNAIDS goal
of 90% at 12 months. In South Africa, overall adherence was
much lower and adherence interruptions of 7+ days were
more common in pregnant women and those with late-stage
HIV infection compared to early-stage HIV infection. Viral sup-
pression in South Africa reached the UNAIDS goal in individu-
als initiating ART with early-stage HIV infection, but not in the
other groups.
Our study adds important effectiveness data from publicly
operated HIV programs in sub-Saharan Africa. The high levels
of viral suppression among individuals with early-stage HIV
infection in our study are consistent with both the multi-
national START trial and the TEMPRANO trial in Côte
d/Ivoire, which demonstrated the personal health benefits of
early ART initiation [5,37]. In START, viral suppression at
12 months was 98% among individuals with CD4 counts
>500 cells/lL who started ART immediately and 97% among
those who waited to initiate ART (i.e. until the CD4 count
dropped <350 cells/lL or they developed AIDS or another
condition requiring ART). In TEMPRANO, viral suppression at
12 months was lower overall, but still >80% for all partici-
pants regardless of timing of ART initiation. Data, however,
were missing for 13% of participants reaching 12 months of
follow up. Adherence was not reported in either study, but
was likely high given the known relationship between adher-
ence and viral suppression. Unlike these trials, our findings
reflect observation of routine clinical care with only three
study visits occurring over one year for approximately 90% of
participants. While adherence monitoring could have acted as
an adherence intervention (i.e. the Hawthorne effect), our
results bode well for individuals initiating ART with high CD4
counts outside of research studies. A recent trial of stream-
lined clinical care in Uganda and Kenya, the SEARCH trial, also
found high levels of viral suppression among individuals with
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p < 0.001
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Figure 2. ART adherence and viral suppression among participants by study setting (Uganda vs. South Africa) and group: men and non-preg-
nant women with early-stage HIV infection (CD4 > 350 cells/lL), pregnant women with early-stage HIV infection and men and non-preg-
nant women with late-stage HIV infection (CD4 < 200 cells/lL).
(A) Percent median adherence, whereas (B) shows the number of 7+ day consecutive interruptions in adherence. (C) Percent viral suppression.
Table 2. Antiretroviral therapy (ART) adherence by HIV stage at ART initiation, stratified by country
Factor
Univariable findings Multivariable findingsa
Percentage point change (95% CI) p-Value Percentage point change (95% CI) p-Value
Uganda
Group
Early/non-pregnant Ref 0.18 ref 0.65
Early/pregnant 4.4 (9.5, 0.7) 0.093 0.3 (4.6, 5.2) 0.91
Late/non-pregnant 2.9 (7.3, 1.5) 0.191 1.7 (5.5, 2.2) 0.40
South Africa
Group
Early/non-pregnant Ref <0.001 ref <0.001
Early/pregnant 22.7 (31.1, 14.4) <0.001 19.2 (28.7, 9.7) <0.001
Late/non-pregnant 13.3 (19.8, 6.7) <0.001 12.1 (18.7, 5.6) <0.001
Values greater than zero indicate higher adherence; values less than zero indicate lower adherence.
aControlling for age, employment, exchange of sex for money, structural barriers, instrumental support, severe food insecurity and use of
medications other than ART in Uganda; and age, marital status, employment, structural barriers, instrumental support, perceived necessity of ART,
physical well-being and cigarette smoking in South Africa.
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high CD4 counts, although adherence again was not assessed
directly [38].
While overall adherence was high among non-pregnant indi-
viduals starting ART with early-stage HIV infection, some
struggled. The predictor analysis showed lower adherence was
associated with younger age and structural barriers in Uganda,
and no regular income, lower stigma, maladaptive coping, lack
of other medication use and cigarette smoking in South Africa.
As global HIV policy increasingly focuses on asymptomatic
PLWH, many of these factors can serve as markers of individ-
uals at risk of low adherence who should be carefully
screened for enhanced counselling, education and other avail-
able interventions. Novel interventions directed at structural
barriers, stigma and maladaptive coping should also be
explored.
Interestingly, social support was not a significant factor, refut-
ing our hypothesis. The impact of social support may have been
limited because we studied individuals engaged in care; those
able to enter care may have access to a basic level of social
support. Additionally, disclosure rates were relatively high and
stigma relatively low, suggesting possible normalization of HIV
care among the populations studied (consistent with global
trends [39]). That said, the association between adherence and
perceived stigma in South Africa suggests stigma avoidance as a
motivating factor; persistent disclosure concerns have also been
observed in another recent South Africa study [40]. An addi-
tional unexpected finding was the lack of effect for beliefs about
ART (i.e. necessity and concern). These factors may have less
impact if social norms promote taking ART and should be
explored in future analyses.
In contrast to the encouraging findings among non-pregnant
women and men with early HIV infection, the low adherence
and viral suppression among pregnant women with high CD4
counts in South Africa are concerning. As presented else-
where [41], baseline factors associated with greater adher-
ence among female participants in South Africa included
incident (vs. prevalent) pregnancy, better coping, belief in the
need for ART and lack of cigarette smoking. A full manuscript
Table 3. Socio-behavioural factors influencing adherence among non-pregnant individuals initiating antiretroviral therapy (ART) with
early HIV infection in Uganda
Factor
Univariable findings Multivariable findings
Percentage point change (95% CI) p-Value Percentage point change (95% CI) p-Value
Female 3.2 (8.3, 2.0) 0.23 – –
Age (increasing by year) 0.7 (0.4, 0.9) <0.001 0.5 (0.3, 0.8) <0.001
Married 2.2 (2.4, 8.9) 0.25 – –
Sexually active 3.0 (6.9, 0.91) 0.13 – –
Education greater than primary 2.9 (8.6, 2.7) 0.31 – –
Literacy in local language 6.7 (12.8, 0.7) 0.30 4.0 (9.5, 1.5) 0.16
Regular income 1.8 (6.4, 2.8) 0.45 – –
Employed 11.1 (1.7, 23.8) 0.09 0.3 (7.7, 8.3) 0.95
Exchanging money for sex 2.7 (3.6, 8.9) 0.40 – –
Structural barriers score 2.1 (3.6, 0.7) 0.005 2.0 (3.3, 0.6) 0.005
Instrumental support 5.6 (0.8, 12.0) 0.09 3.3 (2.9, 9.4) 0.30
Severe food insecurity 3.2 (7.3, 1.0) 0.13 – –
Stigma: perceived negative attitudes towards HIV 0.6 (1.7, 0.5) 0.30 – –
Stigma: disclosure concerns 0.1 (0.8, 0.7) 0.80 – –
Disclosed aside from healthcare provider 4.8 (1.9, 11.6) 0.16 – –
Disclosed outside of household 3.6 (1.3, 8.5) 0.15 – –
Perceived necessity of ART 1.3 (3.1, 5.7) 0.57 – –
Perceived concern for ART 0.7 (4.3, 2.9) 0.70 – –
Maladaptive coping 0.7 (5.3, 3.9) 0.76 – –
Medical mistrust 0.2 (2.0, 2.4) 0.86 – –
Conspiracy 0.7 (1.5, 2.9) 0.52 – –
Clinic satisfaction 1.7 (2.8, 6.1) 0.46 – –
First positive HIV test > 30 days before enrolment 2.7 (3.1, 8.4) 0.36 – –
Use of medications other than ART 14.0 (8.8, 36.9) 0.23 – –
Physical well-being 0.1 (0.2, 0.2) 0.93 – –
Mental well-being 0.1 (0.1, 0.3) 0.26 – –
Probable depression 0.4 (3.8, 4.7) 0.84 – –
Heavy alcohol use 2.7 (8.4, 3.0) 0.35 – –
Smoke cigarettes 1.0 (7.3, 5.4) 0.76 – –
Values greater than zero indicate higher adherence; values less than zero indicate lower adherence.
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detailing the relationships between pregnancy and adherence
and viral suppression at the two study sites, as well as implica-
tions for potential interventions, is in progress. Rollout of uni-
versal lifelong therapy for pregnant and breastfeeding women
(i.e. Option B+) has been shown to increase ART uptake and
initial indications of retention are reasonably high with 77% in
care in Malawi [42]. However, loss-to-follow-up rates have
been as high as 58% when women start ART at large clinics
on the day of HIV diagnosis [43]. Similar findings have been
reported in Mozambique where loss-to-follow-up rates are
38% among women initiating ART with CD4 counts
>350 cells/lL [44]. In contrast, data from another South Afri-
can study found viral suppression rates of 74% at 12 months
for women with same day initiation of ART with Option B+
[45]. Together, these findings call for further research and
interventions to identify and support women struggling during
this vulnerable time.
Similarly, moderate levels of adherence and viral suppres-
sion among individuals with late-stage HIV infection warrants
continued support for this population. A meta-analysis showed
CD4 counts at presentation to care and ART initiation in sub--
Saharan Africa did not increase between 2003 and 2013 [19].
Additional research is needed to see the impact of WHO rec-
ommendations on universal ART access; however, attention is
clearly needed to identify individuals living with HIV earlier
and support them to access treatment.
Our study has many strengths including detailed adherence
data, thorough socio-behavioural metrics, large sample size,
diverse clinical settings, observation of routine clinical care
provision and high retention (approximately 90% for all
groups). Limitations include potential misclassification of
adherence, principally due to device non-use. The relatively
higher degree of viral suppression with lower levels of adher-
ence in South Africa could suggest more device non-use in
that setting. Technical malfunction with the devices and/or cel-
lular transmission of data may have also contributed to mis-
classification of adherence, although adherence data were
available for 97% of participant-days and no technical
Table 4. Socio-behavioural factors influencing adherence among non-pregnant individuals initiating antiretroviral therapy (ART) with
early HIV infection in South Africa
Factor
Univariable findings Multivariable findings
Percentage point change (95% CI) p-Value Percentage point change (95% CI) p-Value
Female 4.3 (14.1, 5.6) 0.40 – –
Age (increasing by year) 0.2 (0.2, 0.7) 0.28 – –
Married 6.6 (4.7, 17.9) 0.25 – –
Sexually active 2.1 (11.9, 7.6) 0.67 – –
Education greater than primary 0.9 (12.0, 10.1) 0.87 – –
Literacy in local language 2.0 (18.5, 14.6) 0.82 – –
Regular income 6.3 (0.44, 12.2) 0.035 6.7 (1.0, 12.4) 0.04
Employed 3.7 (5.6, 13.0) 0.44 – –
Exchanging money for sex 6.0 (62.8, 50.8) 0.84
Structural barriers scale 0.5 (1.0, 0.1) 0.015 0.5 (0.9, 0.1) 0.06
Instrumental support 1.1 (6.8, 9.0) 0.78 – –
Severe food insecurity 3.9 (1.7, 9.5) 0.17 – –
Stigma: perceived negative attitudes towards HIV 1.5 (0.2, 3.3) 0.090 1.9 (0.1, 3.7) 0.04
Stigma: disclosure concerns 0.3 (1.7, 1.2) 0.73 – –
Disclosed aside from healthcare provider 2.2 (10.2, 14.6) 0.73 – –
Disclosed outside of household 2.7 (6.6, 12.0) 0.57 – –
Perceived necessity of ART 4.7 (3.9, 13.3) 0.30 – –
Perceived concern for ART 1.6 (9.6, 6.3) 0.69 – –
Maladaptive coping 15.0 (26.0, 4.0) 0.007 14.4 (23.7, 5.2) 0.002
Medical mistrust 2.9 (4.6, 10.3) 0.45 – –
Conspiracy 0.1 (7.3, 7.2) 0.99 – –
Clinic satisfaction 4.7 (1.1, 10.5) 0.11 – –
First positive HIV test > 30 days before enrolment 3.7 (14.3, 6.9) 0.50 – –
Use of medications other than ART 12.2 (4.8, 19.6) 0.001 9.8 (2.9, 16.7) 0.005
Physical well-being 0.5 (0.8, 0.1) 0.011 0.2 (0.5, 0.2) 0.38
Mental well-being 0.2 (0.1, 0.5) 0.13 – –
Probable depression 5.5 (12.0, 1.0) 0.10 – –
Heavy alcohol use 11.3 (19.7, 2.9) 0.009 5.6 (13.3, 2.1) 0.15
Smoke cigarettes 12.2 (22.2, 2.2) 0.017 12.0 (20.7, 3.2) 0.007
Values greater than zero indicate higher adherence; values less than zero indicate lower adherence.
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challenges were observed for 90% of participants. Additionally,
we only followed individuals for 12 months. An estimated
one-third of individuals fail therapy at two years [46] and the
longitudinal impact of stage of disease at treatment initiation
remains unknown. Finally, 17% of screened individuals
declined to participate in the study. If these individuals were
less likely to achieve high adherence, differential selection
could have biased our estimates of adherence upward.
5 | CONCLUSIONS
In sum, our study shows promise that adherence is high in most
non-pregnant individuals initiating ART with early HIV disease,
thus supporting the universal roll out of ART. However, adher-
ence interventions may be needed for youth and those with no
regular income, no prior experience taking medication, struc-
tural barriers, maladaptive coping skills and cigarette use;
adherence trends should also be assessed with longer follow
up. The challenges seen among pregnant women and those
entering care late in South Africa call for differentiated care
models (i.e. provision of services that are tailored to the needs
of a given individual or sub-population to improve outcomes
and efficiencies within health systems). While modelling data
suggest an AIDS-free generation may be possible and commu-
nity-based “fast-track” ART initiation can achieve high rates of
virological suppression [47], recent data on reducing HIV
incidence has been disappointing [48,49]. More data are
needed to understand the mechanisms behind these findings
and the role adherence plays, particularly among vulnerable
populations.
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Table A2. Baseline participant characteristics among individuals who completed versus did not complete the study due to loss to
follow up, disenrollment or death
Characteristic Completed Lost/disenrolled/died p-Value
Enrollment (N) 805 99 –
Group 0.06
Early/non-pregnant 308 (38) 27 (27)
Early/pregnant 183 (23) 22 (22)
Late/non-pregnant 314 (39) 50 (51)
Median CD4 count (cells/lL)
For participants >350 451 (399–526) 458 (412–528) 0.35
For participants <200 120 (60–160) 90 (50–150) 0.18
Median viral load (log10 copies/mL, IQR) 4.4 (3.5, 5.0) 4.7 (4.2, 5.2) 0.004
Female (N, %) 557 (69) 68 (69) 0.92
Mean age (years, SD) 33 (10) 32 (8) 0.54
Married (N, %) 311 (39) 17 (20) <0.001
Sexually active (N, %) 698 (87) 69 (80) 0.09
Highest education (N, %) 0.48
None/primary 223 (28) 21 (24)
Secondary 582 (72) 66 (76)
Literacy (N, %) in the local language (Runyankole or Xhosa) 706 (88) 70 (81) 0.07
Regular income (N, %) 224 (28) 28 (32) 0.39
Employed (N, %) 529 (66) 42 (48) 0.001
Exchanging money for sex (N, %) 49 (6) 4 (5) 0.14
Structural barrier score (mean score, SD) 8 (8) 9 (8) 0.03
Instrumental support (mean score, SD) 30 (12) 33 (13) 0.09
Emotional support (mean score, SD) 33 (14) 35 (13) 0.39
Severe food insecurity (N, %) 373 (46) 51 (59) 0.02
Stigma: perceived negative attitudes (mean score, SD) 2.2 (1.9) 2.3 (2.0) 0.67
Stigma: disclosure concerns (mean score, SD) 3.6 (2.5) 3.0 (2.5) 0.03
Disclosed aside from healthcare provider (N, %) 635 (79) 70 (81) 0.60
Disclosed outside of household (N, %) 362 (45) 39 (45) 0.95
Perceived necessity of ART (N, %) 0.47
High 231 (29) 29 (34)
Moderate 343 (43) 37 (43)
Low 231 (29) 20 (23)
Perceived concern for ART (N, %) 0.09
High 101 (13) 6 (6)
Moderate 288 (36) 40 (47)
Low 416 (52) 40 (47)
Maladaptive coping (mean, SD) 2.3 (0.3) 2.3 (0.4) 0.37
Medical mistrust (mean, SD) 2.0 (0.7) 2.1 (0.6) 0.62
Conspiracy (mean, SD) 2.1 (0.7) 2.2 (0.6) 0.09
Clinic satisfaction (mean, SD) 3.3 (0.5) 3.2 (0.4) 0.02
First positive HIV test > 30 days prior to enrolment (N, %) 415 (54) 32 (39) 0.01
Use of medications other than ART (N, %) 435 (54) 36 (41) 0.025
Physical well-being (mean, SD) 41 (7) 41 (8) 0.95
Mental well-being (mean, SD) 42 (11) 38 (11) 0.003
Probable depression (N, %) 283 (35) 38 (44) 0.10
Heavy alcohol use (N, %) 141 (18) 19 (22) 0.30
Cigarette use (N, %) 127 (16) 21 (24) 0.04
ART, antiretroviral therapy; IQR, interquartile range. Data were missing for some characteristics as reflected in the percentage presented. Maxi-
mum missing data was <10%
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